Commentary

The Group delivered healthy operating results in the half year under review despite a challenging operating environment characterised by political uncertainty and high levels of unemployment impacting on consumer spending. In a highly competitive environment, each of the business units reported growth in sales and trading profits.

In line with the Group’s strategy, in September 2017 Adcock Ingram concluded a share purchase agreement to acquire 100% of the shares of Genop Holdings Proprietary Limited (Genop). Genop is a highly specialised instrument, surgical and pharmaceutical products company focussed on the ophthalmic, optometry, skincare, aesthetic and plastic surgery segments in Southern Africa.
Read more

Salient features

Continuing Operations
Turnover increases 7% to R3,199 million
Gross profit improves 13% to R1,215 million
Trading profit increases 25% to R428 million
Headline earnings per share from continuing operations increases 33%
Net cash position of R492 million
Dividend declared: 86 cents per share
B-BBEE level 3 achieved


Corporate information

Incorporated in the Republic of South Africa (Registration number 2007/016236/06) Income tax number 9528/919/15/3 Share code: AIP ISIN: ZAE000123436 (“Adcock Ingram” or “the Company” or “the Group”).... Read more

Corporate information